Onco Actu du 8 septembre 2015

	1. Biologie
Science Snaps: prioritising the gene faults behind bowel cancer [Cancer Research UK] “It’s still early days, but all together our findings reinforce just how important the Wnt pathway is in cancer. Our next steps will be to see what combinations of these faults are required to kick start these tumours in people, and whether drugs targeting these signals can stop this.”
	3.1 Tabac
Study: anti-smoking drug Champix does not raise risk of suicide or depression [The Telegraph] The drug is prescribed on the NHS to around 340,000 in England, with the backing of health watchdogs.
	4.10 Dép., diag. & prono. - Poumon
Lung Screening May Not Push Smokers to Quit [NY Times] The results of an admittedly small but telling new study suggest that Medicare and other insurers could be spending billions of dollars on screening smokers for lung cancer that would be better spent on helping them quit and keeping others from starting.
	5.12 Immunothérapies
Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer [BMS] In both trials, Opdivo showed an estimated 18 month overall survival (OS) rate of 27% (CheckMate -063) to 28% (CheckMate -017); survival benefit was independent of PD-L1 expression.
New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer [BMS] These updated results include findings from the administration of four new dosing schedules of Opdivo+Yervoy (n=148), which resulted in confirmed objective response rates (ORR) ranging from 13% to 39% depending on the administered regimen.
Bristol pairs Yervoy safely with Opdivo vs lung cancer [Reuters] Company researchers on Monday released updated data from a Phase I study, called Check Mate-12, that involved 148 previously untreated patients with squamous and non-squamous lung cancer. It compared results of four available drug regimens that paired Opdivo and Yervoy.
	5.2.1 Pharma - Partenariats
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester [AstraZeneca] The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.
	5.2.3 Pharma - économie
Peter Thiel Backs Biotech “Unicorn” Fighting Cancer Stem Cells [MIT Technology Review] The company is unusual because it’s betting on a scientific idea that’s not universally accepted—that cancer is caused not by any cell that goes rogue, but by rare and powerful cancer stem cells.
	5.4 Traitements - Economie
NICE recommends pembrolizumab for advanced skin cancer [NICE] Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS).
UK backs use of Merck cancer immunotherapy after price discount [Reuters] The drug costs about $150,000 for a year of treatment in the United States but will sell for less in Britain. The scale of the discount being offered to Britain's health service is commercially confidential, NICE said.
Companies struggle to get new medicines adopted across Europe [Reuters] While a number countries have pledged in recent years to encourage the use of innovative medicines, Europe remains a much tougher market than the United States, prompting many companies to offer significant price discounts.
	5.6 ESMO
Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress [Genentech] Pivotal results for atezolizumab in urothelial bladder cancer and non-small cell lung cancer.
	6. Lutte contre les cancers
New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer [Boehringer Ingelheim] A holistic approach to lung cancer care should be adopted to ensure patients and carers receive the support and information they need.
Gynaecological cancer: 'women are literally dying of embarrassment' [The Guardian] If my patient had come a few months ealier, she would have been cured with a simple operation.
	6.11 Patients
How long do I have? Story of a myeloma patient [Cancer World] The patient rejects the standard of care. The oncologist cannot answer his question How long do I have? Is the treatment course they agree on second best, or best?